Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo

Journal of Molecular and Cellular Cardiology

Volumn 51, Issue 6, 2011, Pages 1007-1014

  Hoyer, Friedrich Felix ^a   Steinmetz, Martin ^a   Zimmer, Sebastian ^a   Becker, Astrid ^a   Lütjohann, Dieter ^a   Buchalla, Rainer ^b   Zimmer, Andreas ^a   Nickenig, Georg ^a  

^a UNIVERSITY OF BONN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Atherosclerosis; Cannabinoids; CB2; Vascular biology; Vascular inflammation

Indexed keywords

APOLIPOPROTEIN E; CANNABINOID 2 RECEPTOR; REACTIVE OXYGEN METABOLITE; TETRAHYDROCANNABINOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ROOT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL WALL; BONE MARROW CELL; CELL CULTURE; CHEMOLUMINESCENCE; CHOLESTEROL DIET; CONTROLLED STUDY; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PRESSURE; BONE MARROW TRANSPLANTATION; CHOLESTEROL; ENDOCANNABINOIDS; ENDOTHELIAL CELLS; ENDOTHELIUM; HEART RATE; LEUKOCYTES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REACTIVE OXYGEN SPECIES; RECEPTOR, CANNABINOID, CB2;

MUS;

EID: 80055107075     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2011.08.008     Document Type: Article

References (21)

1. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med Apr 21 2005, 352(16):1685-1695.
2. Steffens S., Veillard N.R., Arnaud C., Pelli G., Burger F., Staub C., et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature Apr 7 2005, 434(7034):782-786.
3. Klein T.W., Newton C., Larsen K., Lu L., Perkins I., Nong L., et al. The cannabinoid system and immune modulation. J Leukoc Biol Oct 2003, 74(4):486-496.
4. Berdyshev E.V. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids Nov 2000, 108(1-2):169-190.
5. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature Aug 9 1990, 346(6284):561-564.
6. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature Sep 2 1993, 365(6441):61-65.
7. Bisogno T., Ligresti A., Di Marzo V. The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav Jun 2005, 81(2):224-238.
8. Guindon J., Hohmann A.G. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol Jan 2008, 153(2):319-334.
9. Xu H., Cheng C.L., Chen M., Manivannan A., Cabay L., Pertwee R.G., et al. Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J Leukoc Biol Sep 2007, 82(3):532-541.
10. Malfait A.M., Gallily R., Sumariwalla P.F., Malik A.S., Andreakos E., Mechoulam R., et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A Aug 15 2000, 97(17):9561-9566.
11. Sanchez A.J., Gonzalez-Perez P., Galve-Roperh I., Garcia-Merino A. R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4 -benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor. Biochem Pharmacol Dec 15 2006, 72(12):1697-1706.
12. Arevalo-Martin A., Vela J.M., Molina-Holgado E., Borrell J., Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci Apr 1 2003, 23(7):2511-2516.
13. Melis M., Pillolla G., Luchicchi A., Muntoni A.L., Yasar S., Goldberg S.R., et al. Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J Neurosci Dec 17 2008, 28(51):13985-13994.
14. Tiyerili V., Zimmer S., Jung S., Wassmann K., Naehle C.P., Lutjohann D., et al. CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function. Basic Res Cardiol Jul 2010, 105(4):465-477.
15. Rajesh M., Mukhopadhyay P., Batkai S., Hasko G., Liaudet L., Huffman J.W., et al. CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol Oct 2007, 293(4):H2210-H2218.
16. Rajesh M., Mukhopadhyay P., Hasko G., Huffman J.W., Mackie K., Pacher P. CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol Jan 2008, 153(2):347-357.
17. Zhao Y., Yuan Z., Liu Y., Xue J., Tian Y., Liu W., et al. Activation of cannabinoid CB2 receptor ameliorates atherosclerosis associated with suppression of adhesion molecules. J Cardiovasc Pharmacol Mar 2010, 55(3):292-298.
18. Han K.H., Lim S., Ryu J., Lee C.W., Kim Y., Kang J.H., et al. CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc Res Dec 1 2009, 84(3):378-386.
19. Sugamura K., Sugiyama S., Nozaki T., Matsuzawa Y., Izumiya Y., Miyata K., et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation Jan 6 2009, 119(1):28-36.
20. Freeman-Anderson N.E., Pickle T.G., Netherland C.D., Bales A., Buckley N.E., Thewke D.P. Cannabinoid (CB2) receptor deficiency reduces the susceptibility of macrophages to oxidized LDL/oxysterol-induced apoptosis. J Lipid Res Nov 2008, 49(11):2338-2346.
21. Montecucco F., Burger F., Mach F., Steffens S. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol Mar 2008, 294(3):H1145-H1155.